STERIS Q1 revenue $1.5B (+7%), adj EPS $2.59; announces $55-70M restructuring plan

STERIS plc

Revenue $1.5B (+7% YoY); constant currency organic growth 6%. Adjusted EPS $2.59 vs $2.34 prior year.
Healthcare segment revenue $1.05B (+8%); AST $297.6M (+6%); Life Sciences $146.7M (+9%).
Operating cash flow $367.1M (down from $420M); free cash flow $279.6M (down from $326.5M).
Restructuring: consolidation of chemistries to NC Center of Excellence; closure of St. Louis and Plymouth facilities; pre-tax charges $55-70M, completion by fiscal 2030.
FY2027 guidance reaffirmed: revenue growth 7-8%, adj EPS $11.10-$11.30; CapEx raised to ~$450M, FCF now ~$800M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.